GET DAILY SIGNALSDBV Technologies (DBVT) Q3 2026 Earnings Preview: Focus Shifts to BLA Submission
Key Takeaways
- DBV Technologies is scheduled to report third quarter 2026 financial results on Wednesday, October 28, 2026, after the market close, followed by a conference call at 5:00 p.m. ET.
- Wall Street consensus points to a net loss of approximately $0.14 per American Depositary Share (ADS), with revenue expected near $0.66 million.
- The company remains pre-revenue; its "operating income" primarily reflects the French research tax credit rather than product sales.
- Investors will focus on the planned Biologics License Application (BLA) for the VIASKIN Peanut patch in children aged 4 to 7, which management expects to submit in the third quarter of 2026.
- Cash and cash equivalents stood at $174.9 million as of June 30, 2026, extending the company's runway into the third quarter of 2027.
Why This Earnings Report Matters for DBV Technologies (DBVT)
For DBV Technologies (DBVT), a late-stage biopharmaceutical company developing treatments for food allergies, quarterly earnings are less about revenue than about execution. The company is navigating a transition from clinical-stage developer toward commercial-ready organization ahead of a potential U.S. launch of its VIASKIN Peanut patch. The upcoming report arrives as management works toward a Biologics License Application (BLA) submission for children aged 4 to 7, making expense trends, cash runway, and regulatory milestones the true center of attention. Investors will also watch clinical updates across the COMFORT Toddlers, THRIVE, and VITESSE programs, which shape the company's longer-term allergy franchise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect DBV Technologies (DBVT) to post a net loss of roughly $0.14 per American Depositary Share (ADS) for the third quarter of 2026, with consensus revenue near $0.66 million. Because the company has no approved product on the market, its reported revenue largely reflects the French research tax credit, which has been trending lower as eligible clinical activity winds down and the focus shifts to commercial preparation.
Expenses are the more meaningful line items. In the second quarter of 2026, research and development (R&D) spending rose alongside selling, general, and administrative (SG&A) costs as the company built pre-commercial inventory and U.S. infrastructure. The company reported a net loss of $50.4 million for the second quarter and $98.0 million for the first half of 2026. Investors will be watching whether these cost trends continue and how they affect the cash position, which totaled $174.9 million at mid-year.
Market Reaction and Investor Sentiment
Sentiment heading into the report centers on regulatory progress rather than quarterly numbers. DBV Technologies (DBVT) shares have historically shown muted moves around earnings, and the company has carried a negative post-earnings drift in recent periods. The stock's direction is likely to hinge on management commentary regarding the BLA submission timeline, any feedback from the U.S. Food and Drug Administration (FDA), and updates on cash runway. A delay in the BLA filing or an unexpected increase in cash burn would likely weigh on sentiment, while confirmation of on-track submission and disciplined spending could be viewed constructively.
Forward Outlook and Key Factors to Monitor
The most important catalyst to watch after this report is the actual BLA submission for VIASKIN Peanut in children aged 4 to 7. Management has guided toward filing in the third quarter of 2026, and confirmation of that timing, along with any FDA acceptance and potential priority review designation, will be central to the investment narrative.
Beyond the filing, investors should track the COMFORT Toddlers safety study, where enrollment was completed in the second quarter of 2026, and the topline results expected to follow. The recently initiated THRIVE Phase 2 study in infants aged 6 to 12 months also represents a longer-term expansion of the franchise.
On the financial side, expense discipline and the cash runway remain critical. With $174.9 million in cash as of June 30, 2026, management has indicated sufficient resources into the third quarter of 2027, but pre-commercial inventory builds and U.S. launch preparation could accelerate spending. Any revision to that runway guidance, or signs that additional financing may be needed, would be important signals for shareholders to evaluate.
AI Tools in My Research Workflow
In my day-to-day analysis, I find Tickeron’s AI Screener helpful for quickly scanning biotechnology peers and spotting patterns that complement fundamental research. It lets me filter by industry, market cap, and technical signals in one place, which saves time when preparing for events like this earnings release. The tool has become a regular part of how I cross-check ideas before diving deeper into company-specific filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DBVT in upward trend: price may jump up because it broke its lower Bollinger Band on October 02, 2026
DBVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 42 cases where DBVT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBVT's RSI Oscillator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on DBVT as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for DBVT just turned positive on October 20, 2026. Looking at past instances where DBVT's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBVT advanced for three days, in 161 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DBVT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.908) is normal, around the industry mean (3.037). P/E Ratio (-2.851) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (75.432) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. DBVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non invasive epicutaneous diagnostics systems and immunotherapy for allergy diagnostics
Industry Biotechnology
Advertisement